In the last 2 weeks of August, the Food and Drug Administration (FDA) approved three new cancer drugs: vemurafenib (Zelboraf), for patients with unresectable or metastatic melanoma whose tumors harbor a specific genetic mutation in the BRAF gene; brentuximab vedotin (Adcetris), for some patients with Hodgkin lymphoma and anaplastic large cell lymphoma; and crizotinib (Xalkori), for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors have a gene fusion caused by a chromosomal translocation involving the ALK gene. Read more > >
The associate director of NCI's Radiation Research Program discusses his research and specialized initiatives of the program.
- NIH Seeks Ideas for Common Fund
- Research Funds for Provocative Questions Now Available
- National Cancer Advisory Board Meets Next Week
- President Proclaims September Childhood Cancer Awareness Month
- Research to Reality Cyber-Seminar: Guide to Community Preventive Services
- NCI Conference Focuses on Technologies for Detecting and Diagnosing Cancer in Low- and Middle-Income Countries
Selected articles from past issues of the NCI Cancer Bulletin are available in Spanish.
The NCI Cancer Bulletin is produced by the National Cancer Institute (NCI), which was established in 1937. Through basic, clinical, and population-based biomedical research and training, NCI conducts and supports research that will lead to a future in which we can identify the environmental and genetic causes of cancer, prevent cancer before it starts, identify cancers that do develop at the earliest stage, eliminate cancers through innovative treatment interventions, and biologically control those cancers that we cannot eliminate so they become manageable, chronic diseases.
For more information about cancer, call 1-800-4-CANCER or visit http://www.cancer.gov.
NCI Cancer Bulletin staff can be reached at email@example.com.